Abstract
We disclose novel amphiphilic ruthenium and osmium complexes that auto-assemble into nanomedicines with potent antiproliferative activity by inhibition of mitochondrial respiration. The self-assembling units were rationally designed from the [M(p-cymene)(1,10-phenanthroline)Cl]PF6 motif (where M is either RuII or OsII) with an appended C16 fatty chain to achieve high cellular activity, nano-assembling and mitochondrial targeting. These amphiphilic complexes block cell proliferation at the sub-micromolar range and are particularly potent towards glioblastoma neurospheres made from patient-derived cancer stem cells. A subcutaneous mouse model using these glioblastoma stem cells highlights one of our C16 OsII nanomedicines as highly successful in vivo. Mechanistically, we show that they act as metabolic poisons, strongly impairing mitochondrial respiration, corroborated by morphological changes and damage to the mitochondria. A genetic strategy based on RNAi gave further insight on the potential involvement of microtubules as part of the induced cell death. In parallel, we examined the structural properties of these new amphiphilic metal-based constructs, their reactivity and mechanism.
| Original language | English |
|---|---|
| Pages (from-to) | 2594-2607 |
| Number of pages | 14 |
| Journal | Inorganic Chemistry Frontiers |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| State | Published - Apr 12 2022 |
Bibliographical note
Publisher Copyright:© 2022 The Royal Society of Chemistry.
Funding
M. M. thanks Véronique Megalizzi and Michel Gelbcke for helpful discussions and guidance on the analysis of video microscopy experiments, the team of the Analytical Platform of the Faculty of Pharmacy (ULB) for the record of MS spectra and the team of G-time laboratory (ULB) for the ICP-MS experiments. We would also like to thank Dr Tomoko Sengoku and Mr Michael Alstott for the support with our redox metabolism experiments, supported by the shared resource(s) of the University of Kentucky Markey Cancer Center (P30CA177558). This research was partially funded by NCI R50 CA243706-02 for MON, NCI R01 CA258421-01 for SGA, by the Fédération Wallonie-Bruxelles (EG/MA/JCD/CBV 19-24) for M. M. and by the Belgian Brain Tumor Support (BBTS) for V. M.; G. B. was the recipient of an FRS-FNRS award.
| Funders | Funder number |
|---|---|
| Belgian Brain Tumor Support | |
| University of Kentucky Markey Comprehensive Cancer Center | P30CA177558 |
| National Childhood Cancer Registry – National Cancer Institute | R01 CA258421-01, R50 CA243706-02 |
| Fédération Wallonie-Bruxelles | EG/MA/JCD/CBV 19-24 |
ASJC Scopus subject areas
- Inorganic Chemistry